Compositions derived from <i>Galenia Africana </i>and methods of use for cancer treatment

Abstract

The present invention discloses a cancer treatment method which includes the step of treating a patient having cancer with an extract from Galenia Africana L. plant. The extract may include pinocembrin and/or 2′,4′ dihydroxychalcone and/or 7-hydroxyflavanone. The cancer may be breast cancer or melanoma. The composition may be solubilized with MPG and/or Suganate.

Claims

1. A cancer treatment composition which includes a therapeutically effective amount of an extract from the plant Galenia africana, wherein the extract is solubilized with mono-propylene glycol (MPG) and/or sodium laurylglucosides hydroxypropylsulfonate.

2. The composition as claimed in claim 1, in which the extract includes pinocembrin and/or 2′,4′ dihydroxychalcone and/or 7-hydroxyflavanone.

3. The composition as claimed in claim 1, in which the cancer is breast cancer.

4. The composition as claimed in claim 1, in which the cancer is melanoma.

5. A method of treating cancer in a patient in need thereof, comprising administering to the patent a therapeutically effective amount of the composition of claim 1.

6. The method as claimed in claim 5, in which the extract includes pinocembrin and/or 2′, 4′ dihydroxychalcone and/or 7-hydroxyflavanone.

7. The method as claimed in claim 5, in which the cancer is breast cancer.

8. The method as claimed in claim 5, in which the cancer is melanoma.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The invention will now be described with reference to the figures as follows.

(2) FIG. 1 is a graph for MCF-7 human breast cancer cells treated with GA extract fractionates (8-16-16-repeat) comparing cell survival (percent of control) versus treatment dosages.

(3) FIG. 2 is a graph for MCF-7 human breast cancer cells treated with GA extract fractionates comparing cell survival (percent of control) with treatment dosages.

(4) FIG. 3 is a graph for MCF-7 human breast cancer cells treated with GA extracts (MTT Assay 1) comparing percent viability with KB05 concentration (μg/ml).

(5) FIG. 4 is a graph of MCF-7 human cancer breast cells treated with GA extracts (MTT Assay 2) comparing percent viability with K605 concentration (μg/ml).

(6) FIG. 5 is a graph for MCF-7 human breast cancer cells treated with GA extracts (Cell Titer Glo Assay) comparing percent viability with K605 concentration (μg/ml).

(7) FIG. 6 is a graph for MDA-MB231 human breast cancer cells treated with GA extracts (Cell Titer Glo Assay) comparing percent viability with KB05 concentration (μg/ml).

(8) FIG. 7 is a graph for ME1402 human melanoma cells treated with GA extracts comparing survival with dosage.

(9) FIG. 8 is a graph for MCF12A human breast cells treated with KB extracts comparing cell survival with dosage.

DETAILED DESCRIPTION OF INVENTION

(10) The invention will now be described by way of example.

(11) According to the invention, a cancer treatment method includes the steps of treating a patient having cancer with an extract from Galenia Africana L. plant.

(12) Also according to the invention, a cancer treatment composition includes an extract from Galenia Africana L. plant.

(13) The extract may include pinocembrin and/or 2′,4′ dihydroxychalcone and/or 7-hydroxyflavanone.

(14) The cancer may be breast cancer.

(15) The cancer may be melanoma.

(16) The composition may be solubilized.

(17) The composition may be solubilized with MPG and/or Suganate.

Experiment 1

(18) The objective of the experiment was to test the role of Galenia Africana (GA) extracts on the proliferation of MCF-7 human breast cancer cells. Cells were treated with B1, B2, B3, D1, D1B2 or D1B3. D1 exhibited the most cytotoxicity (IC50 of 26.53 μg/ml), followed by B2 (IC50 of 32.28 μg/ml). Based on the chemical composition of these extracts, it is clear that those that contain high levels of 2′,4′ dihydroxychalcone have the most effect. Indeed, a combination of D1 and B3 at 50:50 ratio had minimal effect as compared to a combination of D1 and B2 at 70:30 ratio.

(19) The results are shown in FIGS. 1 and 2.

(20) TABLE-US-00001 TABLE 1 IC50s of GA extracts on MCF-7 human breast cancer cells B1 73.84 μg/ml B2 46.68 μg/ml D1 26.53 μg/ml D1B2 32.28 μg/ml

(21) TABLE-US-00002 TABLE 2 Chemical compositions of GA extracts with emphasis on pinocembrin and 2′,4′ dihydroxychalcone Items, % pinocembrin 2′,4′-dihydroxychalcone B1 20.46 14.95 B2 40.86 42.97 B3 90.09 1.38 D1 75

Experiment 2

(22) The objective of the experiment was to test the role of Galenia Africana extracts on the proliferation of MCF-7 human breast cancer cells.

(23) The results are shown in FIGS. 3 and 4.

(24) TABLE-US-00003 Chemical compositions of GA extracts 2′,4′- 2′,4′- Batches 7-hydroxyflavanone pinocembrin dihydroxychalcone dihydroxydihydrochalcone LC0524(1) 3.3% 9.6% 7.6% 3.1% LC0525(2) 3.0% 8.4% 6.8% 2.8% LC0535(3) 2.4% 4.3% 3.4% 0.7% Batch 4 2.4% 12.4% 8.9% 3.2%

(25) TABLE-US-00004 Batches IC50 value (μg/mL) LC0524(1) 146.0 LC0525(2) 93.39 LC0535(3) 195.6 Batch 4 148.1 Current 187.1

(26) TABLE-US-00005 IC50 value Batches (μg/mL) LC0524(1) 124.2 LC0525(2) 114 LC0535(3) 132 Batch 4 144.1 Batch 5 141.6

(27) TABLE-US-00006 IC50 value Batches (μg/mL) LC0524(1) 144.2 LC0525(2) 130.5 LC0535(3) 166.3 Batch 4 160.8 Batch 5 158.4

(28) FIG. 7 depicts ME1402 human melanoma cells treated with GA extracts after 48 hrs of incubation. Mean cell survival calculated as percentage of the mean vehicle control.

(29) FIG. 8 depicts MCF12A human breast cells treated with KB extracts after 48 hrs of incubation. Mean cell survival calculated as percentage of the mean vehicle control.